Chemotherapie

  • Rolf W. Seiler
Part of the Schriftenreihe Neurologie / Neurology Series book series (NEUROSER, volume 22)

Zusammenfassung

Neoplastisches Gewebe unterscheidet sich durch rasches, unkontrolliertes Wachstum von Normalge webe, während der Zellmetabolismus der beiden Gewebsarten nicht wesentlich verschieden ist. Deswegen gibt es auch keine spezifische Chemotherapie, die nur gegen Tumorzellen wirkt und das normale Gewebe nicht beeinträchtigt, wie zum Beispiel bei der antibakteriellen Chemotherapie, welche die spezifischen metabolischen Unterschiede zwischen Bakterien und Wirtsgewebe ausnützt und damit eine gezielte Behandlung ohne große Nebenwirkungen auf das normale Gewebe ermöglicht. Die antineoplastische Chemotherapie ist eine unspezifische antiproliferative Behandlung, welche die Tatsache ausnützt, daß das rasche Wachstum eines Tumors nicht der rascheren Teilungsgeschwindigkeit der Tumorzellen zuzuschreiben ist, sondern einer größeren Wachstumsfraktion, d. h. einem größeren Anteil an proliferierenden Zellen im Verhältnis zur Gesamtzahl der Zellen des Tumors. Zur rationalen Planung und Beurteilung der Erfolgsaussichten einer Chemotherapie sollten deswegen die Proliferationscharakteristika des zu behandelnden Neoplasmas bekannt sein.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Andersen AP, Scandinavian Glioblastoma Study Group (1981) Combined modality theray of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47:649PubMedCrossRefGoogle Scholar
  2. 2.
    Ausman JI, Levin VA, Brown WE et al. (1977) Brain tumor chemotherapy. J Neurosurg 46:155PubMedCrossRefGoogle Scholar
  3. 3.
    Bellot PA, Valdiserri RO (1979) Multiple pulmonary lesions in a patient treated with BCNU for glioblastoma multiforme. Cancer 43:46PubMedCrossRefGoogle Scholar
  4. 4.
    Boldrey E, Sheline G (1966) Delayed transitory clinical manifestations after radiation treatment of intracranial tumors. Acta Radio (Ther) (Stockh) 5:5CrossRefGoogle Scholar
  5. 5.
    Broder LE, Rall DP (1972) Chemotherapy of brain tumors. Prog Exp Tumor Res 17:373PubMedGoogle Scholar
  6. 6.
    Brouty-Boye G, Constans JP (1976) Action comparative in vitro de divers agent anti-mitotique sur des lignées cellulaires établies à partir de tumeurs cérébrales humaines. Neurochirurgie 22:69PubMedGoogle Scholar
  7. 7.
    Burger PC, Mahaley MS, Dudka L et al. (1979) The morphologie effects of radiation administered therapeutically for intracranial gliomas. Cancer 44:1256PubMedCrossRefGoogle Scholar
  8. 8.
    Djerassi J, Kim JS, Shulman K (1977) High-dose MTX/Citrovorum factor rescue in the management of brain tumors. Cancer Treat Rep 61:691PubMedGoogle Scholar
  9. 9.
    Eckman WW, Patlak CS, Fenstermacher JD (1974) A critical evaluation of the principles governing the advantages of intraarterial infusions. J Pharmacokinet Biopharm 2:257PubMedCrossRefGoogle Scholar
  10. 10.
    Edland RW, Javid M, Ansfiels FJ (1971) Glioblastoma multiforme. An analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-FU. AJR 111:337Google Scholar
  11. 11.
    EORTC Brain Tumor Group (1978) Evaluation on survival rate of objective remission and duration of free interval in patients with malignant brain glioma. Eur J Cancer 14:851Google Scholar
  12. 12.
    EORTC Brain Tumor Group (1981) Evaluation of CCNU, VM 26 and procarbazine in supra tentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg 55:27CrossRefGoogle Scholar
  13. 13.
    Fewer SA, Wilson CB, Boldrey EB et al. (1972) The chemotherapy of brain tumors: Clinical experience with BCNU and vincristine. JAMA 222:549PubMedCrossRefGoogle Scholar
  14. 14.
    Garfield J, Davan AD (1973) Postoperative intracavitary chemotherapy of malignant gliomas. J Neurosurg 39:315PubMedCrossRefGoogle Scholar
  15. 15.
    Garfield J, Dayan AD, Weller RO (1975) Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol 1:213PubMedGoogle Scholar
  16. 16.
    Geran RI, Congleton GF, Dudeck LE et al. (1974) A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother Rep 4:53Google Scholar
  17. 17.
    Gutin PH, Wilson CB, Kumar VAR et al. (1975) Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35:1398PubMedCrossRefGoogle Scholar
  18. 18.
    Hayakawa T, Ushio Y, Mogami H et al. (1974) The uptake, distribution and antitumor activity of bleomycin in gliomas in the mouse. Eur J Cancer 10:137PubMedGoogle Scholar
  19. 19.
    Hayakawa T, Ushio Y, Morimoto H et al. (1976) Uptake of bleomycin by human brain tumors. J Neurol Neurosurg Psychiatr 39:341PubMedCrossRefGoogle Scholar
  20. 20.
    Heiss WD, Turnheim M, Mamoli B (1978) Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine amethopte-rin and procarbazine. Eur J Cancer 14:1191PubMedGoogle Scholar
  21. 21.
    Hildebrand J, Brihaye J (1978) Chemotherapy of brain tumors. In: Krayenbühl H, Brihaye J, Loew F, Logue V, Mingrino S, Pertuiset B, Symon L, Troupp H, Yasargil MG (eds) Advances and technical standards in neurosurgery, vol 5. Springer, Wien New York, p 75Google Scholar
  22. 22.
    Hildebrand J, Brihaye J, Wagenknecht L et al. (1973) Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Eur J Cancer 11:585Google Scholar
  23. 23.
    Hochberg FH, Slotnick B (1980) Neuropsychologic impairment in astrocytoma survivors. Neurology (NY) 30:172–177Google Scholar
  24. 24.
    Hoshino T (1976) Cell kinetics of malignant brain tumors. In: Fewer D, Wilson CB, Levin VA (eds) Brain tumor chemotherapy. Thomas, Springfield, pp 16–41Google Scholar
  25. 25.
    Hoshino T (1979) The cell kinetics of gliomas: Its prognostic value and therapeutic implications. Neurooncology 1:105–112Google Scholar
  26. 26.
    Hoshino T, Wilson CB (1975) Review of basic concepts of cell kinetics as applied to brain tumors. J Neurosurg 42:123PubMedCrossRefGoogle Scholar
  27. 27.
    Hoshino T, Wilson CB, Rosenblum ML et al. (1975) Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43:127PubMedCrossRefGoogle Scholar
  28. 28.
    Israel L, Chahinian P (1973) Comparative toxicity on leukocytes and platelets of 2 regimens of CCNU. Eur J Cancer 9:799PubMedGoogle Scholar
  29. 29.
    Jellinger K, Kothbauer P, Vollmer R et al. (1979) Combination chemotherapy (COMP Protocol) and radiotherapy of anaplastic supratentorial gliomas. Acta Neurochir (Wien) 51:1CrossRefGoogle Scholar
  30. 30.
    Jones SE (1974) Failure of Indium-III labeled bleomycin tumor scanning to predict response to bleomycin treatment. Cancer Chemother Rep 58:733PubMedGoogle Scholar
  31. 31.
    Jorgensen SJ (1972) Time-dose relationships in combined bleomycin treatment and radiotherapy. Eur J Cancer 8:531PubMedGoogle Scholar
  32. 32.
    Kennedy BJ, Brown JH, Yarbro JW (1965) Mithramycin therapy for primary glioblastomas. Cancer Chemother Rep 48:59PubMedGoogle Scholar
  33. 33.
    Khandekar JD, Bigner DD (19733) Chemotherapy of brain tumors. The “blood-brain barrier” is not a factor. Arch Neurol 34:523Google Scholar
  34. 34.
    Kumar ARV, Renaudin J, Wilson CB et al. (1974) Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 40:365CrossRefGoogle Scholar
  35. 35.
    Lassman LP, Pearce GW, Gang J (1965) Sensitivity of intracranial gliomas to vincristine sulphate. Lancet 1:296PubMedCrossRefGoogle Scholar
  36. 36.
    Levin VA, Wilson CB (1975) Chemotherapy: The agents in current use. Semin Oncol 2:63PubMedGoogle Scholar
  37. 37.
    Levin VA, Wilson CB (1976) Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat Rep 60:719PubMedGoogle Scholar
  38. 38.
    Levin VA, Crafts DC, Wilson CB et al. (1976) BCNU and procarbazine treatment for malignant brain tumors. Cancer Treat Rep 60:243PubMedGoogle Scholar
  39. 39.
    Levin VA, Hoffman WF, Pischer TL et al. (1978) BCNU/5-FU combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62:2071PubMedGoogle Scholar
  40. 40.
    Levin VA, Kabra PM, Freeman-Dove MA (1978) Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 48:587PubMedCrossRefGoogle Scholar
  41. 41.
    Long DM (1970) Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32:127PubMedCrossRefGoogle Scholar
  42. 42.
    Mamo L, Nouel JP, Robert J et al. (1973) Use of radioactive bleomycin to detect malignant intracranial tumors. J Neurosurg 39:735PubMedCrossRefGoogle Scholar
  43. 43.
    Marks J, Gado M (1977) Serial CT of primary brain tumors following surgery, irradiation and chemotherapy. Radiology 125:119PubMedGoogle Scholar
  44. 44.
    Nakagaki H, Brunhart G, Kemper TL et al. (1976) Monkey brain damage from radiation in the therapeutic range. J Neurosurg 44:3PubMedCrossRefGoogle Scholar
  45. 45.
    Neuwelt EA, Glasberg M, Frenkel E et al. (1980) Is there a therapeutic role for blood-brain barrier disruption? Ann Inter n Med 93:137Google Scholar
  46. 46.
    Norman D, Enzmann DR, Levin VA et al. (1976) Computed tomography in the evaluation of malignant glioma before and after therapy. Radiology 121:85PubMedGoogle Scholar
  47. 47.
    Ohno K, Fredericks R, Rapoport SI (1979) Osmotic opening of the blood-brain barrier to MTX in the rat. Surg Neurol 12:323PubMedGoogle Scholar
  48. 48.
    Ommaya AK (1963) Subcutanous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet 11:983CrossRefGoogle Scholar
  49. 49.
    Owens G, Javid R, Belmusto L et al. (1965) Intra-arterial vincristine therapy of primary gliomas. Cancer 18:756PubMedCrossRefGoogle Scholar
  50. 50.
    Poisson M, Haus JJ, Pouillart P et al. (1979) Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Acta Neurochir (Wien) 51:27CrossRefGoogle Scholar
  51. 51.
    Pollay M, Roberts PA (1980) Blood-brain barrier: A definition of normal and altered function. Neurosurgery 6:675PubMedCrossRefGoogle Scholar
  52. 52.
    Pouillart P, Hoang Thy Huong T, Brugerie E et al. (1974) Sequential administration of two oncostatic drugs: Study of modalities for pharmacodynamic potentiation. Biomedicine 21:471PubMedGoogle Scholar
  53. 53.
    Pouillart P, Schwarzenberg L, Amiel JL et al. (1975) Combinations chimiothéra-piques de drogues se potentialisant. Nouv Presse Med 4:721PubMedGoogle Scholar
  54. 54.
    Pouillart P, Mathe G, Thy Th et al. (1976) Treatment of malignant gliomas and brain metastasis in adults with a combination of adriamycin, VM 26 and CCNU. Cancer 38:1909PubMedCrossRefGoogle Scholar
  55. 55.
    Ransohoff J, Lieberman A, Walker MD (1979) Multiple therapies in the management of malignant gliomas. Neurooncology 1:55–68Google Scholar
  56. 56.
    Reagan TJ, Bisel HF, Childs DS et al. (1976) Controlled study of CCNU and radiation therapy in malignant astrocytomas. J Neurosurg 44:186PubMedCrossRefGoogle Scholar
  57. 57.
    Ringkjob R (1968) Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 44:318PubMedCrossRefGoogle Scholar
  58. 58.
    Rosen G, Ghavimi F, Nirenberg A et al. (1977) High-dose MTX with citrovorum factor rescue for the treatment of CNS tumors in children. Cancer Treat Rep 61:681PubMedGoogle Scholar
  59. 59.
    Rosenblum ML, Reynolds AF, Smith KA et al. (1973) CCNU in the treatment of malignant brain tumors. J Neurosurg 39:306PubMedCrossRefGoogle Scholar
  60. 60.
    Rosenstock FG, Evans AE, Schut L (1976) Response to vincristine of recurrent brain tumors in children. J Neurosurg 45:135PubMedCrossRefGoogle Scholar
  61. 61.
    Rozencweig M, Von Hoff DD, Henney J et al. (1977) VM 26 and VP 16–213: A comparative analysis. Cancer 40:334PubMedCrossRefGoogle Scholar
  62. 62.
    Schacht RG, Leiberman AN, Epstein FJ et al. (1979) Chronic interstitial nephritis and renal failure due to nitrosurea therapy. Abstr. of the Int. Symp. on multidisci-plinary aspects of brain tumor therapy, June 8–10, 1979, Gardone, Riviera, pp 25Google Scholar
  63. 63.
    Seiler RW (1981) Late results of multimodality therapy of high-grade supratentorial astrocytomas. Surg Neurol 15:88PubMedCrossRefGoogle Scholar
  64. 64.
    Seiler RW, Greiner RH, Zimmermann A et al. (1978) Radiotherapy combined with procarbazine, bleomycin and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 48:861PubMedCrossRefGoogle Scholar
  65. 65.
    Seiler RW, Imbach P, Vassella F et al. (1978) Adjuvant chemotherapy with intraventricular MTX and CCNU after surgery and radiotherapy of medulloblastomas. Helv Paediatr Acta 33:235PubMedGoogle Scholar
  66. 66.
    Seiler RW, Reichenbach W, Fricker U et al. (1978) Response to vincristine and procarbazine of recurrent medulloblastomas. Helv Paediatr Acta 33:177PubMedGoogle Scholar
  67. 67.
    Seiler RW, Vassella F, Markwalder H (1979) Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors. Surg Neurol 11:237PubMedGoogle Scholar
  68. 68.
    Seiler RW, Zimmermann A, Markwalder H (1980) Adjuvant chemotherapy with VM 26 and CCNU after operation and radiotherapy of high-grade supratentorial astrocytomas. Surg Neurol 13:65PubMedGoogle Scholar
  69. 69.
    Shapiro WR (1971) Studies on the chemotherapy of experimental brain tumors: Evaluation of CCNU, vincristine and 5-FU. J Natl Cancer Inst 46:359PubMedGoogle Scholar
  70. 70.
    Shapiro WR (1974) The chemotherapy of intracerebral vs subcutanous murine gliomas. Arch Neurol 30:222PubMedCrossRefGoogle Scholar
  71. 71.
    Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors. Evaluation of BCNU, cyclophosphamide, mitramycine and methotrexate. Cancer Res 30:2401PubMedGoogle Scholar
  72. 72.
    Shapiro WR, Young DF (1976) Treatment of malignant glioma. Arch Neurol 33:494PubMedCrossRefGoogle Scholar
  73. 73.
    Shapiro WR, Young DF, Mehta BM (1975) MTX distribution in CSF after intravenous, ventricular and lumbar injections. N Engl J Med 293:161PubMedCrossRefGoogle Scholar
  74. 74.
    Shealey CN, Crafts D (1955) Selective alteration of blood-brain barrier. J Neuro-surg 23:484Google Scholar
  75. 75.
    Shetter AG, Bertuccini TV, Pittman HW (1977) Closed needle biopsy in the diagnosis of intracranial mass lesions. Surg Neurol 8:341PubMedGoogle Scholar
  76. 76.
    Slansky BD, Manu-Kaplan RS, Reynolds AF et al. (1974) PTG in the treatment of malignant intracranial neoplasms. Cancer 33:460CrossRefGoogle Scholar
  77. 77.
    Sweet DL, Hendler FJ, Hanlon K et al. (1979) Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM 26 following surgery and radiation therapy. Cancer Treat Rep 63:1707PubMedGoogle Scholar
  78. 78.
    Takeuchi K (1975) A clinical trial of intravenous bleomycin in the treatment of brain tumors. Int J Clin Pharmacol Biopharm 12:419PubMedGoogle Scholar
  79. 79.
    Takeuchi K, Hoshino K (1977) Statistical analysis of factors affecting survival after glioblastoma multiforme. Acta Neurochir (Wien) 37:57CrossRefGoogle Scholar
  80. 80.
    Tator CH (1977) Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. Surg Neurol 7:73PubMedGoogle Scholar
  81. 81.
    Tator CH, Wassenaar W, Day A et al. (1977) Therapy of an experimental glioma with systemic or intraneoplastic methotrexate or radiation. J Neurosurg 46:175PubMedCrossRefGoogle Scholar
  82. 82.
    Tranum BL, SWOG (1975) A phase II study of Methyl-CCNU in the treatment of solid tumors and lymphomas. Cancer 35:1148PubMedCrossRefGoogle Scholar
  83. 83.
    Ushio Y, Hayakawa T, Mogami H (1974) Uptake of tritiated MTX by mouse brain tumors after intravenous or intrathecal administration. J Neurosurg 40:706PubMedCrossRefGoogle Scholar
  84. 84.
    Walker MD, Brain Tumor Study Group (1976) Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg. 44:655PubMedCrossRefGoogle Scholar
  85. 85.
    Walker MD, Brain Tumor Study Group (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333PubMedCrossRefGoogle Scholar
  86. 86.
    Walker MD, Brain Tumor Study Group (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323PubMedCrossRefGoogle Scholar
  87. 87.
    Walker MD, Gehan EA (1976) Clinical studies in malignant gliomas and their treatment with the nitrosoureas. Cancer Treat Rep 60:713PubMedGoogle Scholar
  88. 88.
    Walker MD, Hurwitz BS (1970) BCNU in the treatment of malignant brain tumors. Cancer Chemother Rep 54:263PubMedGoogle Scholar
  89. 89.
    Wasserman TH, Slavik M, Carter SC (1975) Clinical comparison of the nitrosoureas. Cancer 36:1258PubMedCrossRefGoogle Scholar
  90. 90.
    Weir B, Band P, Urtasun R et al. (1976) Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 45:129PubMedCrossRefGoogle Scholar
  91. 91.
    Wilson CB (1976) Single-agent chemotherapy of brain tumors. Arch Neurol 33:739PubMedCrossRefGoogle Scholar
  92. 92.
    Young RC, Walker MD, Canellos GP et al. (1973) Initial clinical trial with Methyl-CCNU. Cancer 31:1164PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • Rolf W. Seiler
    • 1
  1. 1.Neurochirurgische Universitätsklinik InselspitalBernSchweiz

Personalised recommendations